HUM-MOLGEN events: Cambridge Healthtech Institute's Linking Phenotype to Genotype

HUM-MOLGEN -> Events -> Meetings and Conferences

Cambridge Healthtech Institute's Linking Phenotype to Genotype

January 28, 2003

Cambridge Healthtech Institute, Hilton Munchen Park, Am Tucherpark 7, D-80538, Munich, Germany
April 24-25, 2003

Phenotypes are generally difficult to recognize and validate, especially at the cellular level. Providing an association between phenotype and genotype is critical to being able to understand and create models of disease. This association is also key to targeting critical pathways in disease and identifying the genes and proteins that regulate biological processes, thus identifying better drug targets. The use of chemical genomics will be a powerful technique for phenotype screening. Case studies and the latest approaches will be highlighted that give clear examples of linking genotype with clinical conditions and the reverse process of using small molecules to probe genotype. The promise of isolating specific disease mechanisms on the basis of both forward and reverse genetics is that it will enable both disease prevention and early intervention. The ability to correlate clinical phenotype with genotype will give highly validated targets for drug discovery, improve the models that are used for drug testing, and provide rationale for improved clinical trial designs. This will result in a greater success rate for drug development.

Organized by:

Cambridge Healthtech Institute

Invited Speakers:

Dr. S. Lee Adamson, University of Toronto
Dr. Reuven Agami, Netherlands Cancer Institute
Prof. Steve D.M. Brown, MRC Mammalian Genetics Unit and UK Mouse Genome Centre
Dr. Hans Clevers, UMC Utrecht
Dr. Martin Hrabe de Angelis, GSF-Institute of Experimental Genetics
Dr. Paz Einat, Quark Biotech, Inc. (USA) & QBI Enterprises (Israel)
Dr. José Luis Pérez Gracia, Eli Lilly & Co., Inc.
Dr. Jonathan Hall, Novartis Pharmaceutical Corporation
Dr. Christoph Hüls, Protagen AG
Dr. Curtis T. Keith, CombinatoRx, Inc.
Dr. Hans Lehrach, Max-Planck-Institüt für Molekulare Genetik
Dr. Michael C. Nehls, Ingenium AG
Dr. Smita Patel, Merck Sharp & Dohme
Dr. Ketty Schwartz, INSERM
Dr. Gill Smith, AstraZeneca R&D Charnwood
Dr. Giulio Superti-Furga, Cellzome AG
Dr. Hans-Peter Vornlocher, Ribopharma AG
Dr. Claes Wahlestedt, Karolinska Institute
Dr. Lutz Weber, Morphochem AG

Deadline for Abstracts:

March 21, 2003

Registration:

Available Online phone:617-630-1300/fax: 617-630-1325 e-maiil: chi@healthtech.com

E-mail:

eeskedal@healthtech.com

Posted by:

elaine eskedal

Host:

wks152.healthtech.com